Spinout News

Freeline publishes preclinical proof-of-concept data for FLT190, its AAV gene therapy candidate for Fabry disease, in the Nature Journal Gene Therapy

20 January 2023

Freeline logo

Freeline Therapeutics has announced the publication of preclinical proof-of-concept data for its gene therapy candidate for Fabry disease, FLT190, in the Nature journal Gene Therapy. Fabry disease is a debilitating genetic disorder in which an enzyme deficiency leads to a harmful build-up of fat in the cells that causes progressive organ damage and can result in early death.

Freeline is a clinical-stage biotechnology company developing transformative gene therapies for people with inherited systemic debilitating diseases. In 2020, they announced their IPO on Nasdaq which raised $158.8m.

Read more from Freeline here.